Laurion Capital Management LP C4 Therapeutics, Inc. Transaction History

Laurion Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$5.3 - $11.0 $2.84 Million - $5.89 Million	535,342 New	535,342 $4.37 Million
Q2 2023 Aug 14, 2023	BUY	$2.75 - $3.77 $71,453 - $97,955	25,983 New	25,983 $71,000
Q1 2022 May 16, 2022	SELL	$19.99 - $33.23 $11.6 Million - $19.3 Million	-581,028 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$29.39 - $46.86 $2.39 Million - $3.82 Million	-81,435 Reduced 12.29%	581,028 $18.7 Million
Q3 2021 Nov 15, 2021	SELL	$35.91 - $50.5 $5.49 Million - $7.72 Million	-152,941 Reduced 18.76%	662,463 $29.6 Million
Q2 2021 Aug 13, 2021	BUY	$30.39 - $42.18 $16.6 Million - $23.1 Million	547,399 Added 204.25%	815,404 $30.9 Million
Q1 2021 May 14, 2021	BUY	$31.96 - $46.5 $5.06 Million - $7.37 Million	158,405 Added 144.53%	268,005 $9.91 Million
Q4 2020 Feb 12, 2021	BUY	$22.8 - $37.05 $2.5 Million - $4.06 Million	109,600 New	109,600 $3.63 Million

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $208M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.